ASST Ospedale Maggiore di Crema

The ASST Ospedale Maggiore di Crema is conducting research focused on advanced HER2‑negative and PD‑L1 positive gastroesophageal adenocarcinoma, aiming to improve outcomes through a switch‑maintenance strategy that combines chemotherapy and immunotherapy.

• Evaluation of paclitaxel as part of maintenance therapy
• Role of ramucirumab in anti‑angiogenic treatment
• Use of tislelizumab to enhance immune response
• Impact of HER2‑negative status on therapeutic choices
• Significance of PD‑L1 positive biomarkers

Findings aim to extend progression‑free survival for patients with this digestive system cancer.

In the field of skin cancer, the site is evaluating a novel antibody, ABP 206, against the established checkpoint inhibitor nivolumab for patients with unresectable or metastatic melanoma who have not received prior systemic therapy.

• Comparison of ABP 206 with standard immunotherapy
• Assessment of response in first‑line treatment setting
• Investigation of immune checkpoint inhibition mechanisms
• Monitoring of safety and tolerability profiles
• Exploration of biomarkers predictive of benefit

The study seeks to determine whether the new agent can provide a more effective treatment option for patients with advanced melanoma.